GLP-1 Clinic Marketing Compliance Checklist
A practical do-and-do-not checklist for marketing a GLP-1 clinic without crossing FTC or FDA lines, or your medical board's.
Why does GLP-1 marketing carry extra compliance risk?
Because it sits on regulated medicine. You are describing prescription medications, clinician-determined eligibility, and sometimes compounded drugs. The FTC polices deceptive claims and fake reviews; the FDA polices drug claims; and your state medical board polices professional advertising. Marketing that ignores these does not just risk penalties, it erodes the trust that earns patients in the first place.
What should GLP-1 clinic marketing do?
- Describe the consultation, eligibility, and provider oversight accurately
- State that eligibility is clinician determined and not every patient qualifies
- Have a licensed provider review every clinical, drug, and safety claim before launch
- Describe compounded medications accurately and never as FDA-approved
- Use real reviews; attribute them honestly
What should it never do?
- No guaranteed or specific weight-loss outcome claims
- No fake before-and-after promises
- No "miracle", "safe for everyone", or "no side effects" language
- No implication that compounded GLP-1 drugs are FDA-approved
- No fabricated patient testimonials or invented case studies
Primary sources
These are the authoritative references behind the rules above. Read them directly rather than relying on summaries, and have your provider and counsel confirm how they apply to your clinic.
- FDA — FDA's concerns with unapproved GLP-1 drugs used for weight loss. The FDA's statement on compounded and other unapproved GLP-1 products, including why compounded drugs are not FDA-approved.
- FTC — Health Products Compliance Guidance. The FTC's guidance on substantiating health claims and avoiding deceptive advertising and reviews.
How KailxLabs keeps the build compliant
We build the marketing and visibility layer and defer every clinical, drug, and safety claim to your licensed provider for review before launch. We do not write outcome promises, fake reviews, miracle copy, or FDA-approval implications for compounded medications. See how this runs through the GLP-1 clinic AI search optimization build, the prompt library, pricing, or get a free GLP-1 AI visibility report.
Common questions
Who should review GLP-1 marketing copy?
A licensed medical provider at the clinic should review any clinical, drug, eligibility, or safety claim before it is published. Marketing teams and agencies write the visibility layer; the provider owns the medical claims.
Are compounded GLP-1 claims allowed?
You can describe compounded medications, but you must do so accurately and must never imply they are FDA-approved. Misleading compounded-drug language is a common and serious compliance failure.